 infection increases host cell mutation frequency by unknown
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host cell mutation frequency
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Background: Microsporidia are obligate intracellular opportunistic fungi that cause significant pathology in
immunocompromised hosts. However, 11 percent of immunocompetent individuals in the general population
are microsporidia-seropositive, indicating that severe immune suppression may not be a prerequisite for infection.
Encephalitozoon intestinalis is transmitted in contaminated water and initially infects gastro-intestinal enterocytes,
leading to diarrheal disease. This organism can also disseminate to many other organs. A recent report suggests
that microsporidia can establish persistent infections, which anti-fungal treatment does not eradicate. Like other
intracellular pathogens, microsporidia infection stresses the host cell and infected individuals have elevated
hydrogen peroxide and free radical levels.
Findings: As oxidative stress can lead to DNA damage, we hypothesized that E. intestinalis-infection would increase
host cell nuclear mutation rate. Embryo fibroblasts from Big BlueTM transgenic mice were E. intestinalis-infected and
host nuclear mutation frequency was determined by selection of temperature-sensitive c-II gene mutant λ phage.
The host mutation frequency in E. intestinalis-infected cultures was 2.5-fold higher than that observed in either
mock-infected cells or cells infected with UV-inactivated E. intestinalis spores.
Conclusions: These data provide the first evidence that microsporidia infection can directly increase host cellular
mutation frequency. Additionally, some event in the microsporidia developmental cycle between host cell attachment
and parasitophorous vacuole formation is required for the observed effect. As there is considerable evidence linking
infection with other intracellular pathogens and cancer, future studies to dissect the mechanism by which E. intestinalis
infection increases host mutation frequency are warranted.
Keywords: Encephalitozoon intestinalis, Microsporidia infection, Microsporidiosis, Big Blue™ mouse, Mutation frequency,
Opportunistic infections and cancerFindings
Background
Microsporidia are intracellular parasitic fungi that infect
many animals, including humans. Microsporidiosis in the
immunocompromised first became evident during the
Acquired Immunodeficiency Syndrome (AIDS) pandemic,
but remains a concern in Human Immunodeficiency Virus
(HIV)-infected individuals without access to therapy, as
well as those immunosuppressed due to cancer therapy,
diabetes, organ transplants, and autoimmune disease [1].
However, 11% of HIV-negative individuals in the general
population are Microsporidia seropositive, suggesting that
while overt disease may not be widespread, asymptomatic* Correspondence: hayman@etsu.edu
Department of Biomedical Sciences, James H. Quillen College of Medicine,
East Tennessee State University, Johnson City, TN 37614-0579, USA
© 2013 Leonard et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orinfections of healthy individuals are relatively common
[2]. Kotkova et al. demonstrated that Encephalitozoon
cuniculi-infected, albendazole-treated BALB/c mice can
develop disseminated infection if they are immunosup-
pressed post-treatment [3]. As chronic microsporidia
infections occur in humans [4], these data suggest such
infections may be refractory to treatment [3]. Thus,
microsporidia are important emerging pathogens and
are classified by the US National Institutes of Health as
Biodefense Category B agents.
An estimated 2 million infectious disease-linked cancer
cases occurred worldwide in 2008, many attributable to
intracellular pathogens like Human Papilloma Virus [5].
Infection with the obligate intracellular bacterium
Chlamydia trachomatis which, like many microsporidia
species, replicates in a cytoplasmic parasitophorousl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Leonard et al. Infectious Agents and Cancer 2013, 8:43 Page 2 of 5
http://www.infectagentscancer.com/content/8/1/43vacuole (PV), increases host cellular chromosomal in-
stability in culture [6] and is associated with increased
cervical cancer risk in vivo [7]. Like other obligate
intracellular pathogens, microsporidia exert significant
stress on infected host cells. Microsporidia infection
alters host cell cycle regulation [8] and can lead to
development of multinucleated host cells [9,10]. Mul-
tinucleated cells also occur in human tumors and can
give rise to lung metastases in nude mice [11]. Micro-
sporidia infection also inhibits p53-associated, caspase
3-mediated apoptosis [12] - an important mechanism by
which some viruses promote host cellular transformation.
Finally, oxidative stress markers, such as hydrogen per-
oxide, free radicals and lipid peroxides, are elevated in
microsporidium-infected patients [13]. Though reactive
oxygen species are generated during beneficial anti-
microbial host responses, they also increase both host
DNA damage and cancer risk [14]. Thus, we tested the
hypothesis that microsporidia infection increases the
host cell nuclear mutation rate within infected cultures.Approach
The Big Blue™ transgenic mouse (Agilent Technologies,
Inc.) measures in vivo mutational frequency in response
to genotoxic insults and contains ~40 chromosomally-
integrated copies of the λ-phage genome as a mutation
target [15]. After mutagen exposure, Big Blue™ mouse
genomic DNA is packaged into λ phage capsids. Phage
that are wild type at the cII locus will not plaque at 24°C
in G1250 E. coli, but mutational inactivation of the cII
gene allows lytic replication at 24°C. In contrast, both
cII mutant and cII-wild type phage produce plaques at
37°C [16]. Thus, Big Blue™ cell nuclear mutation can be
quantified by dividing the number of cII-mutant plaques
obtained at 24°C by the total number of plaques at 37°C.
We obtained heterozygous Big Blue™ murine embryonic
fibroblasts (BB-MEFs) by crossing homozygous male
Big Blue™ mice with female BALB/c mice. The tissue,
minus head and peritoneal cavity contents, from 2–2.5-
week-old embryos was minced and trypsinized. Single
cell suspensions were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS) and frozen in liquid nitrogen until use.
Infectious E. intestinalis spores were propagated in
Vero African Green Monkey kidney cells (ATCC CCL-
81) cultured in DMEM with 2% FBS. After 10–12 days
in culture, spores were harvested by centrifugation,
washed with 0.25% sodium dodecyl sulfate and sterile
water, counted and stored as described [17]. E. intestinalis
spores (E. intestinalisUV) were inactivated by 1.14 J/cm
2
of ultraviolet (UV) light in a Spectroline XL-1500 cross
linker and did not produce PVs in subsequent infec-
tions (Figure 1A).Results
To ascertain infected cell mutation frequency, BB-MEFs
were mock-infected (exposed to medium without spores),
E. intestinalis-infected or infected with E. intestinalisUV
at 37°C for 42 hours (h). In preliminary time course
studies, 42 hours post-infection (hpi) was the latest
time at which no difference in host cell death between
mock- and E. intestinalis BB-MEFs was observed. Genomic
DNA, purified from replicate cultures, was packaged into λ
phage capsids in vitro. G1250 E. coli suspensions were
infected with phage populations, plated in soft agar and
incubated either under non-selective (37°C) conditions
for 16 h or selective (24°C) conditions for 48 h [18]. All
putative mutant plaques were re-plaqued at 24°C before
scoring as mutants and the cII mutation frequency was
determined as described above. Interestingly, the cII
mutation frequency was increased by 2.5-fold in E.
intestinalis productively-infected versus mock-infected
cells (Figure 1B; 7.84 × 10-5+/−1.19 × 10-5 versus 3.07 ×
10-5 +/−1.08 × 10-5; p = 0.04). In contrast, the mutation
frequency in BB-MEFs exposed to E. intestinalisUV was
similar to that in mock-infected cells (3.69 × 10-5+/−1.08 ×
10-5 versus 3.07 × 10-5 +/−1.08 × 10-5; p = 0.70). These
data indicate that: i) microsporidia infection increases
host nuclear mutation frequency 2–3 fold; and ii) the
observed mutation frequency increase depends upon
infection with viable spores.
To confirm infection, E. intestinalis-infected BB-MEF
cells were stained with Uvitex 2B (a chitin-specific,
fluorescent stain that labels free microsporidia spores
and those within PVs) and DAPI (to label host cell
nuclei), and intracellular microsporidia PVs and host
nuclei were counted. Approximately 8% infection was
achieved in E. intestinalis-infected BB-MEFs at 42 hpi
(Figure 1C). E. intestinalis-infected BB-MEFs contained
morphologically-normal PVs (Figure 1A and [19]). In
contrast, PVs were absent in mock- and E. intestinalisUV-
infected cells (Figure 1A,C). UV-inactivated spores
adhered to BB-MEFs (Figure 1A), suggesting that spore
attachment alone does not increase host mutation
frequency. To eliminate the possibility that mutation
frequency was increased by DNA damage subsequent
to pathogen-induced host cell death, dead cells were
quantified in all experimental groups. No significant
difference was observed in percent dead cells at 42 hpi
between the groups (Figure 1D). Furthermore, average
host cell nuclei/field was the same in all groups (see
Additional file 1: Figure S1). Thus, the host cell nuclear
mutation rate increase is not an artifact of host cell death.
Discussion
These data demonstrate that: i) E. intestinalis infection
increases host mutation frequency in culture; and ii) this
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Figure 1 Productive E. intestinalis infection increases host cellular nuclear mutation frequency. BB-MEF cultures were: i) mock (mock)-in-
fected; ii) E. intestinalis (E. int.)-infected 5 spores/cell, or iii) infected with ~5 spores/cell of UV-inactivated, E. intestinalis (E. int.UV) refed with DMEM,
and incubated at 37°C. Panel A. Fluorescent micrographs from mock, E. intestinalis- or E. intestinalisUV-infected BB-MEFs at 42 hpi. Photographs
were taken at 630× (oil immersion) using an ultraviolet filter for simultaneous visualization and morphological differentiation of DAPI-stained host
cell nuclei and Uvitex-stained spores and parasitophorous vacuoles (PV), all of which appear blue. Because Uvitex-stained spores and PVs fluoresce
comparatively more intensely, host cell nuclei are circled to improve visualization. Symbols: N = host cell nucleus; sp = spore; PV = parasitophorous
vacuole. Scale bars are 10 microns. Panel B. At 42 hpi, 1 x 107 cells were trypsinized, pelleted, quick-frozen, and stored at −80°C. Genomic DNA
was purified using the RecoverEase DNA Isolation kit (Agilent Technologies, Inc.). Transpack (Agilent Technologies, Inc.) extracts were used to package
genomic λ-phage DNA. Packaged phages were analyzed for cII mutation frequency as described. Panel C. At 42 hpi, BB-MEF cultures on coverslips were
acetone:methanol fixed, stained with 0.01% Uvitex 2B (Polysciences, Inc.) and 1 ug/ml 4’,6-Diamidino-2-Phenylindole, Dichloride (DAPI; Life
Technologies, Inc.), and mounted in Vectashield (Vector Laboratories, Inc.). Infectious foci and host cell nuclei were counted in 20 random
630x fields/coverslip using an Olympus BH-2 fluorescent microscope. Percentage of infected cells/reticle was then calculated. Panel D. At 42
hpi, BB-MEF cultures on coverslips were assayed using the “Live/Dead” cell viability kit (Molecular Probes, Inc.). Average number of dead cells/
400x reticle in 20 random fields/group is plotted. In panels B-D, results average 3 replicates in 3 independent experiments. Means were compared with
the unpaired Student’s t test using Microsoft Excel; p values < 0.05 = significant. NS = not significant.
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not detect mutations: i) in other parts of the phage/
host genome; or ii) that do not alter cII gene function,
these data likely underestimate MEF nuclear mutation
frequency. However, this assay determines whether muta-
tion frequency changes under different experimental
conditions – such as infection with various pathogens. Forexample, gastric infection with the bacterium Helicobacter
pylori and liver infection with the fluke Fasciola hepatica
increase Big Blue™ mouse mutation frequencies 5-fold
and 2-fold in vivo, respectively [18,20]. Although we
cannot determine absolute mutation frequency in
microsporidia-infected cells, the data clearly demonstrate
that microsporidia infection is genotoxic. The magnitude
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within the range observed for other pathogens [18,20]
and the carcinogen N-ethyl-N-nitrosourea [21]. It is likely,
however, that a higher mutation frequency would be ob-
served if infection efficiencies higher than 8% (Figure 1C)
could be obtained without reducing host cell viability.
Microsporidia infection could increase host cellular
mutation frequency by several mechanisms. First, micro-
sporidia-infected patients have elevated levels of reactive
chemical species [13], suggesting that microsporidia-
induced, oxidative DNA damage may elevate host DNA
mutation frequency. Second, microsporidia could secrete
effectors that directly damage host DNA or indirectly
increase mutation frequency by interfering with host
DNA repair. For example, H. hepaticus and other Gram-
negative pathogens secrete cytolethal distending toxins
that damage host DNA and increase host cell genomic
instability [22]. Notably, microsporidia infection interferes
with p53-induced apoptosis [12], indicating that this
pathogen may secrete effectors that manipulate pathways
linking DNA repair and apoptosis. In either case, mutation
frequency in uninfected “bystander” cells may increase,
promoting tumor formation even if infected cells do not
survive. Finally, the E. intestinalis PV may interfere with
host DNA segregation, as does that of C. trachomatis [6].
As the Big Blue™ assay can neither determine the specific
DNA damage mechanism nor discriminate between
infected cells and non-infected bystander cells, a more
detailed evaluation of the mechanism by which micro-
sporidia-infection elevates host mutation frequency is
necessary.
Microsporidia can establish chronic infections [4], even
after anti-fungal therapy [3]. Thus, long-term infection
has the potential to significantly alter host genomic stability
within affected organs. Microsporidia also infect chronic-
ally immunosuppressed individuals, who have increased
cancer incidence [23]. Though microsporidiosis is observed
in cancer patients [24,25], it is assumed to be a byproduct
of immunosuppression. The possibility that microsporidia
infection contributes to cancer induction or progression
has not, therefore, been seriously considered. Our data
indicate a possible connection between microsporidiosis
and cancer induction that should be further explored.
Though the immune response helps control microsporidia
infection, inflammation-derived reactive oxygen species
can damage DNA. Furthermore, growth factors and cyto-
kines associated with inflammation may support cellular
proliferation, migration and metastasis, contributing to
cancer development independent of DNA damage. Al-
though microsporidia infection is unlikely to be a proximal
cause for cancer, it is plausible that chronic infection, in
combination with other genotoxic insults, would increase
cancer risk in individuals who contract microsporidiosis,
even if infection is asymptomatic.Additional file
Additional file 1: Figure S1. Microsporidia infection does not induce
host cell loss at 42 hpi. Host nuclei counts were performed on: i) replicate
mock (mock)-infected; ii) E. intestinalis (E. int.)-infected; or iii) UV inactivated,
E. intestinalis (E. int.UV)-infected BB-MEF monolayers. At 42 hpi, BB-MEF cul-
tures on glass coverslips were fixed with 1:1 acetone: methanol and DAPI
stained. Stained cells were mounted in Vectashield (Vector Laboratories, Inc.)
and the number of host cell nuclei were counted in 20 random 630x fields
per coverslip using an Olympus BH-2 fluorescent microscope. Host nuclei/
reticle was then calculated for each group and plotted. The results shown
are averaged from 3 replicates in 3 independent experiments. Means were
compared with the unpaired Student’s t test using Microsoft Excel; p values
below 0.05 were considered significant. NS = not significant.
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